54-96-6 | 3,4-Diaminopyridine

Packsize	Purity	Availability	Price	Discounted Price
100mg	98%	in stock	$11.00	$8.00
1g	98%	in stock	$15.00	$10.00
5g	98%	in stock	$38.00	$27.00
10g	98%	in stock	$61.00	$43.00

Description

• Catalog Number: AB63653
• Chemical Name: 3,4-Diaminopyridine
• CAS Number: 54-96-6
• Molecular Formula: C5H7N3
• Molecular Weight: 109.1292
• MDL Number: MFCD00006401
• SMILES: Nc1cnccc1N
• NSC Number: 521760

Computed Properties

• Complexity: 74.1
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 8
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 2
• XLogP3: -0.5

Literature

• Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist.

  The Journal of physiology 20140815

• Ectopic uterine tissue as a chronic pain generator.

  Neuroscience 20121206

• Reversal of BoNT/A-mediated inhibition of muscle paralysis by 3,4-diaminopyridine and roscovitine in mouse phrenic nerve-hemidiaphragm preparations.

  Neurochemistry international 20121101

• Mutations in DPAGT1 cause a limb-girdle congenital myasthenic syndrome with tubular aggregates.

  American journal of human genetics 20120713

• The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.

  Clinical therapeutics 20120501

• 3,4-Diaminopyridine improves neuromuscular transmission in a MuSK antibody-induced mouse model of myasthenia gravis.

  Journal of neuroimmunology 20120401

• Recurrent COLQ mutation in congenital myasthenic syndrome.

  Pediatric neurology 20120401

• The dynamic relationships between the three events that release individual Na⁺ ions from the Na⁺/K⁺-ATPase.

  Nature communications 20120214

• Content variability of active drug substance in compounded oral 3,4-diaminopyridine products.

  Journal of clinical pharmacy and therapeutics 20120201

• Clinical features in a series of fast channel congenital myasthenia syndrome.

  Neuromuscular disorders : NMD 20120201

• Long-term disease history, clinical symptoms, health status, and healthcare utilization in patients suffering from Lambert Eaton myasthenic syndrome: Results of a patient interview survey in Germany.

  Journal of medical economics 20120101

• Hypotension due to Chemotherapy in a Patient with Small Cell Lung Cancer and Lambert-Eaton Myasthenic Syndrome Undergoing Hemodialysis: A First Case Report.

  Case reports in oncology 20120101

• Nervous System of Periplaneta americana Cockroach as a Model in Toxinological Studies: A Short Historical and Actual View.

  Journal of toxicology 20120101

• The use of aminopyridines in neurological disorders.

  Clinical neuropharmacology 20120101

• The Effects of K(+) Channel Blockade on Eccentric and Isotonic Twitch and Fatiguing Contractions in situ.

  Frontiers in physiology 20120101

• [Aminopyridines for symptomatic treatment of multiple sclerosis].

  Ugeskrift for laeger 20111212

• Comparison of 10-mg doses of 4-aminopyridine and 3,4-diaminopyridine for the treatment of downbeat nystagmus.

  Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 20111201

• John Newsom-Davis: clinician-scientist and so much more.

  Brain : a journal of neurology 20111201

• Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology.

  Neurology 20111108

• Formulating a new basis for the treatment against botulinum neurotoxin intoxication: 3,4-Diaminopyridine prodrug design and characterization.

  Bioorganic & medicinal chemistry 20111101

• One collective case of type A foodborne botulism in Corsica.

  Clinical toxicology (Philadelphia, Pa.) 20111001

• Role of calcium-activated potassium channels in the genesis of 3,4-diaminopyridine-induced periodic contractions in isolated canine coronary artery smooth muscles.

  The Journal of pharmacology and experimental therapeutics 20110901

• Autoimmune neuromuscular disorders.

  Current neuropharmacology 20110901

• Autoimmune channelopathies of the nervous system.

  Current neuropharmacology 20110901

• Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20110817

• Single-pixel optical fluctuation analysis of calcium channel function in active zones of motor nerve terminals.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20110803

• Beneficial effect of albuterol in congenital myasthenic syndrome with epsilon-subunit mutations.

  Muscle & nerve 20110801

• Pharmacotherapy of vestibular and ocular motor disorders, including nystagmus.

  Journal of neurology 20110701

• Preclinical evaluation of caprylic acid-fractionated IgG antivenom for the treatment of Taipan (Oxyuranus scutellatus) envenoming in Papua New Guinea.

  PLoS neglected tropical diseases 20110501

• Medical treatment for botulism.

  The Cochrane database of systematic reviews 20110316

• Effects of 3-4 diaminopyridine (DAP) in motor neuron diseases.

  Journal of clinical neuromuscular disease 20110301

• Treatment for Lambert-Eaton myasthenic syndrome.

  The Cochrane database of systematic reviews 20110216

• A Cys-loop mutation in the Caenorhabditis elegans nicotinic receptor subunit UNC-63 impairs but does not abolish channel function.

  The Journal of biological chemistry 20110128

• Protein kinases modulate store-operated channels in pulmonary artery smooth muscle cells.

  Journal of biomedical science 20110101

• Suramin inhibits the early effects of PLA(2) neurotoxins at mouse neuromuscular junctions: A twitch tension study.

  Journal of venom research 20110101

• Pricing and reimbursement of orphan drugs: the need for more transparency.

  Orphanet journal of rare diseases 20110101

• Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine.

  Neuropsychiatric disease and treatment 20110101

• The neuromuscular activity of Micrurus pyrrhocryptus venom and its neutralization by commercial and specific coral snake antivenoms.

  Journal of venom research 20110101

• Cerebellum and ocular motor control.

  Frontiers in neurology 20110101

• Lambert-eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy.

  Autoimmune diseases 20110101

• Symptomatic relief of botulinum neurotoxin/a intoxication with aminopyridines: a new twist on an old molecule.

  ACS chemical biology 20101217

• Orphan drugs. BioMarin Europe replies.

  BMJ (Clinical research ed.) 20101207

• Orphan drugs. Regulation is flawed.

  BMJ (Clinical research ed.) 20101207

• 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome.

  Expert review of clinical immunology 20101101

• 3,4-Diaminopyridinium 2-carboxy-4,6-dinitrophenolate.

  Acta crystallographica. Section E, Structure reports online 20101101

• State of the art in hereditary muscle channelopathies.

  Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 20101001

• Anharmonic vibrational analysis of 3,4-diaminopyridine and 3-aminopyridine by density functional theory calculations.

  Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20100901

• The price you pay.

  Drug and therapeutics bulletin 20100901

• 3-D-QSAR and docking studies on the neuronal choline transporter.

  Bioorganic & medicinal chemistry letters 20100815

• Guidelines for treatment of autoimmune neuromuscular transmission disorders.

  European journal of neurology 20100701

• Lambert-Eaton myasthenic syndrome as a cause of persistent neuromuscular weakness after a mediastinoscopic biopsy -A case report-.

  Korean journal of anesthesiology 20100701

• Mutations in MUSK causing congenital myasthenic syndrome impair MuSK-Dok-7 interaction.

  Human molecular genetics 20100615

• 3,4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study.

  Journal of neurology 20100601

• Effects of hydroxamate metalloendoprotease inhibitors on botulinum neurotoxin A poisoned mouse neuromuscular junctions.

  Neuropharmacology 20100601

• Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.

  Current medical research and opinion 20100601

• The effect of 3,4-diaminopyridine on the patients with hereditary pure cerebellar ataxia.

  Journal of the neurological sciences 20100515

• Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7.

  Neurology 20100511

• The zinc-dependent protease activity of the botulinum neurotoxins.

  Toxins 20100501

• [Lambert-Eaton myasthenic syndrome (LEMS)].

  Brain and nerve = Shinkei kenkyu no shinpo 20100401

• Neuropharmacology of vestibular system disorders.

  Current neuropharmacology 20100301

• 4-Amino-3-ammonio-pyridinium dinitrate.

  Acta crystallographica. Section E, Structure reports online 20100301

• Quantification of 4-aminopyridine in plasma by capillary electrophoresis with electrokinetic injection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100201

• Effect of pantoprazole and its interactions with vecuronium on the neuromuscular junction.

  Indian journal of pharmacology 20100201

• Improvement of diaphragm and limb muscle isotonic contractile performance by K+ channel blockade.

  Journal of neuroengineering and rehabilitation 20100101

• [Lambert-Eaton myasthenic syndrome associated with pulmonary squamous cell carcinoma and circulating anti-P/Q-type voltage-gated calcium channel antibody].

  Rinsho shinkeigaku = Clinical neurology 20100101

• New methods for diagnosis and treatment of vestibular diseases.

  F1000 medicine reports 20100101

• Eye disorders in patients with multiple sclerosis: natural history and management.

  Clinical ophthalmology (Auckland, N.Z.) 20100101

• Sensing the deadliest toxin: technologies for botulinum neurotoxin detection.

  Toxins 20100101

• Gold and silver nanoparticles conjugated with heparin derivative possess anti-angiogenesis properties.

  Nanotechnology 20091111

• 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS.

  Muscle & nerve 20091101

• {2,2'-[Pyridine-3,4-diylbis(nitrilo-methyl-idyne)]diphenolato}zinc(II).

  Acta crystallographica. Section E, Structure reports online 20091101

• Management of myasthenic conditions: nonimmune issues.

  Current opinion in neurology 20091001

• 3,4-Diamino-pyridinium 4-nitro-benzoate-4-nitro-benzoic acid (1/1).

  Acta crystallographica. Section E, Structure reports online 20090801

• Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.

  Clinical pharmacology and therapeutics 20090701

• Skeletal muscle contraction-induced vasodilator complement production is dependent on stimulus and contraction frequency.

  American journal of physiology. Heart and circulatory physiology 20090701

• 3,4-Diamino-pyridinium hydrogen succinate.

  Acta crystallographica. Section E, Structure reports online 20090701

• Mutations in LAMB2 causing a severe form of synaptic congenital myasthenic syndrome.

  Journal of medical genetics 20090301

• [Treatment approach to congenital myasthenic syndrome in a patient with acetylcholine receptor deficiency].

  No to hattatsu = Brain and development 20090101

• [A case of Lambert-Eaton myasthenic syndrome with small cell lung cancer, treated with 3,4-diaminopyridine].

  Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20090101

• 4-Amino-3-ammonio-pyridinium dichloride.

  Acta crystallographica. Section E, Structure reports online 20090101

• [Pharmacotherapy of central oculomotor disorders].

  Der Nervenarzt 20081201

• Long-lasting in vivo inotropic effects of the K(+) channel blocker 3,4-diaminopyridine during fatigue-inducing stimulation.

  Muscle & nerve 20081201

• Therapeutic strategies in congenital myasthenic syndromes.

  Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20081001

• Lambert-Eaton myasthenic syndrome: search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis.

  Journal of neuroimmunology 20080915

• Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression.

  Brain structure & function 20080901

• Mechanisms of neuromodulation as dissected using Sr2+ at motor nerve endings.

  Journal of neurophysiology 20080601

• Onset dynamics of type A botulinum neurotoxin-induced paralysis.

  Journal of pharmacokinetics and pharmacodynamics 20080601

• Inotropic effects of the K+ channel blocker 3,4-diaminopyridine on fatigued diaphragm muscle.

  Respiratory physiology & neurobiology 20080101

• [Lambert-Eaton Myasthenic Syndrome associated with vocal cord carcinoma].

  Revue neurologique 20080101

• L-type Ca2+ channel function is linked to dystrophin expression in mammalian muscle.

  PloS one 20080101

• Autoantibodies in neuromuscular transmission disorders.

  Annals of Indian Academy of Neurology 20080101

• [Successful treatment of a Lambert-Eaton myasthenic syndrome patient with 3,4-diaminopyridine].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20070810

• Beneficial effects of 3,4-diaminopyridine on positioning downbeat nystagmus in a circumscribed uvulo-nodular lesion.

  Journal of neurology 20070801

• Childhood myasthenia: clinical subtypes and practical management.

  Developmental medicine and child neurology 20070801

• Myasthenia gravis and Lambert-Eaton myasthenic syndrome in the same patient.

  Muscle & nerve 20070701

• Potassium initiates vasodilatation induced by a single skeletal muscle contraction in hamster cremaster muscle.

  The Journal of physiology 20070601

• Molecular docking study of the binding of aminopyridines within the K+ channel.

  Journal of molecular modeling 20070501

• Neuromuscular paralysis and recovery in mice injected with botulinum neurotoxins A and C.

  The European journal of neuroscience 20070501

• The therapy of congenital myasthenic syndromes.

  Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20070401

• Stability studies of ionised and non-ionised 3,4-diaminopyridine: hypothesis of degradation pathways and chemical structure of degradation products.

  Journal of pharmaceutical and biomedical analysis 20070104

• [Treatment of Lambert-Eaton syndrome with 3,4- diaminopyridine and pyridostigmine].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20070101

• Inotropic effects of the K+ channel blocker 3,4-diaminopyridine: differential responses of rat soleus and extensor digitorum longus.

  IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society 20061201

• Altered diaphragm muscle action potentials in Zucker diabetic fatty (ZDF) rats.

  Respiratory physiology & neurobiology 20060928

• Treatment of the gravity dependence of downbeat nystagmus with 3,4-diaminopyridine.

  Neurology 20060912

• Extrusion of Ca2+ from mouse motor terminal mitochondria via a Na+-Ca2+ exchanger increases post-tetanic evoked release.

  The Journal of physiology 20060801

• Pre- and post-synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with 'limb-girdle myasthenia'.

  Brain : a journal of neurology 20060801

• Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment.

  Pharmacology & therapeutics 20060701

• Available treatment options for the management of Lambert-Eaton myasthenic syndrome.

  Expert opinion on pharmacotherapy 20060701

• Guidelines for the treatment of autoimmune neuromuscular transmission disorders.

  European journal of neurology 20060701

• No benefit of 3,4-diaminopyridine in essential tremor: a placebo-controlled crossover study.

  Neurology 20060613

• The effects of presynaptic calcium channel modulation by roscovitine on transmitter release at the adult frog neuromuscular junction.

  The European journal of neuroscience 20060601

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Fetal exposure to 3,4-diaminopyridine in a pregnant woman with congenital myasthenia syndrome.

  The Annals of pharmacotherapy 20060401

• [Fatigue and episodic exhaustion as a feature of multiple sclerosis].

  Revue neurologique 20060301

• [Pathophysiology and treatment of fatigue in multiple sclerosis].

  Revue neurologique 20060301

• NCAM 180 acting via a conserved C-terminal domain and MLCK is essential for effective transmission with repetitive stimulation.

  Neuron 20050616

• Taicatoxin inhibits the calcium-dependent slow motility of mammalian outer hair cells.

  Hearing research 20050501

• Treatment for Lambert-Eaton myasthenic syndrome.

  The Cochrane database of systematic reviews 20050418

• Effect of 3,4-diaminopyridine on the postural control in patients with downbeat nystagmus.

  Annals of the New York Academy of Sciences 20050401

• Cognitive deficits in aged rats correlate with levels of L-arginine, not with nNOS expression or 3,4-DAP-evoked transmitter release in the frontoparietal cortex.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20050301

• Electrophysiological and pharmacological characterization of K+-currents in muscle fibres isolated from the ventral sucker of Fasciola hepatica.

  Parasitology 20041201

• Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries.

  Hypertension (Dallas, Tex. : 1979) 20040901

• Upbeat about downbeat nystagmus.

  Neurology 20040824

• Effect of 3,4-diaminopyridine on the gravity dependence of ocular drift in downbeat nystagmus.

  Neurology 20040824

• Determination of A 3,4-diaminopyridine in plasma by liquid chromatography with electrochemical detection using solid-phase extraction.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040615

• Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine.

  Neurology 20040608

• Distinct phenotypes of congenital acetylcholine receptor deficiency.

  Neuromuscular disorders : NMD 20040601

• Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage.

  Journal of neurology, neurosurgery, and psychiatry 20040601

• Cure of experimental botulism and antibotulismic effect of toosendanin.

  Acta pharmacologica Sinica 20040601

• Combination of variable frequency train stimulation and K+ channel blockade to augment skeletal muscle force.

  IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society 20040601

• Dual effects of nitric oxide in the mouse forced swimming test: possible contribution of nitric oxide-mediated serotonin release and potassium channel modulation.

  Pharmacology, biochemistry, and behavior 20040301

• Novel truncating RAPSN mutations causing congenital myasthenic syndrome responsive to 3,4-diaminopyridine.

  Neuromuscular disorders : NMD 20040301

• Lambert-Eaton myasthenic syndrome.

  Revue neurologique 20040201

• 3,4-DAP-evoked transmitter release in hippocampal slices of aged rats with impaired memory.

  Brain research bulletin 20031215

• [Formulation and stability of hospital preparation of 3,4-diaminopyridine capsules].

  Annales pharmaceutiques francaises 20031101

• Sternohyoid muscle fatigue properties of dy/dy dystrophic mice, an animal model of merosin-deficient congenital muscular dystrophy.

  Pediatric research 20031001

• Lambert-eaton myasthenic syndrome: diagnosis and treatment.

  Annals of the New York Academy of Sciences 20030901

• Wheel-running exercise alters rat diaphragm action potentials and their regulation by K+ channels.

  Journal of applied physiology (Bethesda, Md. : 1985) 20030801

• Potassium channels, the cerebellum, and treatment for downbeat nystagmus.

  Neurology 20030722

• Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study.

  Neurology 20030722

• Rational modelling of the voltage-dependent K+ channel inactivation by aminopyridines.

  Biophysical chemistry 20030601

• Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome.

  Seminars in neurology 20030601

• The vascular response to the K+ channel inhibitor 4-aminopyridine in hypertensive rats.

  European journal of pharmacology 20030418

• Streptozotocin-diabetes alters action potentials in rat diaphragm.

  Respiratory physiology & neurobiology 20030415

• Quantitative estimate of mitochondrial [Ca2+] in stimulated motor nerve terminals.

  Cell calcium 20030301

• Membrane properties related to the firing behavior of zebrafish motoneurons.

  Journal of neurophysiology 20030201

• Exacerbation of Lambert-Eaton myasthenic syndrome caused by an L-type Ca2+ channel antagonist.

  Japanese heart journal 20030101

• Treatment for Lambert-Eaton myasthenic syndrome.

  The Cochrane database of systematic reviews 20030101

• Effect of thymol on kinetic properties of Ca and K currents in rat skeletal muscle.

  BMC pharmacology 20030101

• Raphé grafts and 3,4-diaminopyridine-evoked overflow of serotonin in the rat hippocampus after 5,7-dihydroxytryptamine lesions: evidence for 5-HT1A autoreceptors.

  Neuroreport 20021028

• Analysis of the pressor response to the K+ channel inhibitor 4-aminopyridine.

  European journal of pharmacology 20021011

• Preparation of 3,4-diaminopyridine microparticles by solvent-evaporation methods.

  International journal of pharmaceutics 20020821

• Improvement of dy/dy dystrophic diaphragm by 3,4-diaminopyridine.

  Muscle & nerve 20020701

• The nature of the receptor site for the reversible K+ channel blocking by aminopyridines.

  Biophysical chemistry 20020410

• [Treatment of severe botulism with 3,4-diaminopyridine]].

  Presse medicale (Paris, France : 1983) 20020406

• Potassium channel KV alpha1 subunit expression and function in human detrusor muscle.

  The Journal of urology 20020401

• Action of Micrurus dumerilii carinicauda coral snake venom on the mammalian neuromuscular junction.

  Toxicon : official journal of the International Society on Toxinology 20020201

• Activation thresholds of K(V), BK andCl(Ca) channels in smooth muscle cells in pial precapillary arterioles.

  Journal of vascular research 20020101

• Role of K+ channels in L-6 myoblast migration.

  Journal of muscle research and cell motility 20020101

• Aminopyridines for symptomatic treatment in multiple sclerosis.

  The Cochrane database of systematic reviews 20020101

• [Lambert-Eaton myasthenic syndrome: diagnosis and treatment].

  Clinical calcium 20011101

• Expression and function of native potassium channel [K(V)alpha1] subunits in terminal arterioles of rabbit.

  The Journal of physiology 20010801

• [Quantitative evaluation of the effect of 3,4-diaminopyridine in a patient with Lambert-Eaton myasthenic syndrome using dynamic dynamometry].

  Rinsho shinkeigaku = Clinical neurology 20010801

• Theoretical analysis of the molecular determinants responsible for the K(+) channel blocking by aminopyridines.

  Biophysical chemistry 20010615

• Neuromuscular monitoring in myasthenic syndrome.

  Anaesthesia 20010601

• Electrophysiological analysis of the neurotoxic action of a funnel-web spider toxin, delta-atracotoxin-HV1a, on insect voltage-gated Na+ channels.

  The Journal of experimental biology 20010201

• Modulation of diaphragm action potentials by K(+) channel blockers.

  Respiration physiology 20010201

• Validation of a CE assay for the analysis of isomeric aminopyridines and diaminopyridines.

  Journal of pharmaceutical and biomedical analysis 20010201

• Neurogenic bladder in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine.

  Journal of the neurological sciences 20010115

• [Proximal muscle weakness, depressed tendon reflexes and autonomic dysfunction: the Lambert-Eaton myasthenic syndrome].

  Nederlands tijdschrift voor geneeskunde 20010113

• Development and validation of a capillary electrophoresis assay for the determination of 3,4-diaminopyridine and 4-aminopyridine including related substances.

  Journal of chromatography. A 20010112

• Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle.

  Toxicon : official journal of the International Society on Toxinology 20010101

• Aminopyridines for symptomatic treatment in multiple sclerosis.

  The Cochrane database of systematic reviews 20010101

• Antagonism of botulinum toxin A-mediated muscle paralysis by 3, 4-diaminopyridine delivered via osmotic minipumps.

  Toxicon : official journal of the International Society on Toxinology 20001001

• Antagonism of botulinum toxin-induced muscle weakness by 3,4-diaminopyridine in rat phrenic nerve-hemidiaphragm preparations.

  Toxicon : official journal of the International Society on Toxinology 19950401